OncoMatch/Clinical Trials/NCT06136364
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Is NCT06136364 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CAR-T for t-lymphoblastic lymphoma.
Treatment: CAR-T — To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD7 overexpression (CD7+ by flow cytometry or IHC)
The tumor cells detected by bone marrow flow cytometry were CD7+ and/or extramedullary lesions were diagnosed as CD7+ by pathological immunohistochemistry at the time of enrollment and screening
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard induction chemotherapy
patients who have received at least two courses standard induction regimen and failed to achieve a complete response or complete remission was not achieved after first-line or above salvage treatment
Cannot have received: CAR-T cell therapy
Subjects who have received CAR-T therapy or other gene-modified cell therapy prior to screening
Lab requirements
Blood counts
HGB at least 70g/L, PLT 50x10^9/L, can be transfused
Kidney function
Creatinine <1.5×ULN or creatinine clearance rate(Cockroft-Gault)>50ml/min
Liver function
Total bilirubin <3×ULN; ALT/AST<3×ULN
Cardiac function
Oxygen saturation under air ≥ 92%; LVEF≥50%
Oxygen saturation under air ≥ 92%; LVEF≥50%; Total bilirubin <3×ULN; ALT/AST<3×ULN; Creatinine <1.5×ULN or creatinine clearance rate(Cockroft-Gault)>50ml/min; HGB at least 70g/L,PLT 50x109/L, can be transfused
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06136364 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy disqualifies patients from enrollment.
Does this trial require CD7?
Yes, CD7 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify